Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 0.98 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 0.98 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 0.98 |
| ▸ | CDK9 known ✓ | P50750 | 11/20 | 0.98 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 0.98 |
| ▸ | CCND1 | P24385 | 10/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.98 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.98 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.98 |
| ▸ | GSK3B | P49841 | 4/20 | 0.98 |
| ▸ | GSK3A | P49840 | 4/20 | 0.98 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.98 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.98 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL30848987 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL29772535 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL14719291 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL1181340 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL12445809 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL16927354 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Flavopyridol SCHEMBL22580715 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL3651 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL8214028 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL3652 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | disclosed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | disclosed |
| US-11925618-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2024-03-12 | — | — | US | disclosed |
| US-20220168273-A1 | Pharmaceutical Combination for the Treatment of Cancer | Piramal Enterprises Limited (IN) | 2022-06-02 | — | — | US | disclosed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | disclosed |
| EP-3148532-B1 | PHARMACEUTICAL COMBINATION COMPRISING A CDK INHIBITOR AND A THIOREDOXIN REDUCTASE INHIBITOR FOR THE TREATMENT OF CANCER | PIRAMAL ENTPR LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200138782-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2020-05-07 | — | — | US | disclosed |
| US-10555931-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2020-02-11 | — | — | US | disclosed |
| US-20170112809-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-06-09 | — | — | US | disclosed |
| US-7915301-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one | Piramal Life Science Limited (IN) | 2011-03-29 | — | — | US | disclosed |
| US-7888341-B2 | 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide; antitumor; antiproliferative agent; synergistic therapy for resistant; Bcr/Abl, leukemia | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2011-02-15 | — | — | US | disclosed |
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | disclosed |
| EP-1496908-B1 | COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER | UNIV VIRGINIA COMMONWEALTH (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20050176725-A1 | Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer | THE GOVERNMENT OF THE UNITED STATES, THE DEPARTMENT OF VETERANS AFFAIRS | 2005-08-11 | — | — | US | disclosed |
| EP-1496908-A1 | COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER | Virginia Commonwealth University (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003084543-A1 | COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176725-A1 | Combination of glivec (sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer | CDK2, CDKN1A, CDKL4 | CDK2 1/4885CDK4 7/4885CDK1 23/4885 |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | CDK1, CCNK, CCNI | CDK2 4/4885CDK4 11/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.